Guardant Health, Inc. (NASDAQ:GH) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC cut its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 43.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,534 shares of the company's stock after selling 19,309 shares during the quarter. SG Americas Securities LLC's holdings in Guardant Health were worth $780,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company's stock worth $102,000 after purchasing an additional 796 shares during the last quarter. Fiduciary Alliance LLC grew its position in Guardant Health by 7.6% during the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock worth $363,000 after buying an additional 836 shares in the last quarter. JNBA Financial Advisors acquired a new position in shares of Guardant Health in the third quarter valued at $26,000. Wexford Capital LP lifted its holdings in shares of Guardant Health by 13.0% during the 3rd quarter. Wexford Capital LP now owns 10,081 shares of the company's stock worth $231,000 after acquiring an additional 1,158 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in shares of Guardant Health in the 3rd quarter valued at approximately $34,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Guardant Health Trading Up 4.8 %

GH stock traded up $2.29 during trading on Thursday, reaching $49.94. 3,241,589 shares of the stock were exchanged, compared to its average volume of 2,610,541. The firm has a market cap of $6.17 billion, a P/E ratio of -11.78 and a beta of 1.28. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89. The firm's 50 day moving average is $36.31 and its 200 day moving average is $29.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analysts' expectations of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm's revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.73) earnings per share. As a group, analysts predict that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Transactions at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of the company's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the sale, the director now directly owns 7,648 shares of the company's stock, valued at $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Musa Tariq sold 2,320 shares of the company's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 5,548 shares of company stock worth $179,782. 5.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

GH has been the subject of several recent research reports. The Goldman Sachs Group upped their target price on shares of Guardant Health from $36.00 to $49.00 and gave the company a "buy" rating in a research report on Tuesday. Leerink Partners cut their price target on Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. Barclays began coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They set an "overweight" rating and a $60.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Guardant Health in a research report on Wednesday, January 22nd. Sixteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $42.63.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.